NCT06469944 2026-04-13
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT06662786 2026-04-13
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06750094 2026-04-13
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05253651 2026-04-07
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT06780111 2026-03-31
MK-3475-06E
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06428409 2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06793917 2025-07-20
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital
Phase 3 Recruiting
NCT05319639 2025-02-27
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Fujian Cancer Hospital
Phase 1/2 Recruiting